![Australia Stock Market Today 23/08/2026 [UPDATE: 08:38 AEST] [Healthcare Surge: Weekly Recap and Week Ahead]](https://ts2.tech/wp-content/uploads/2026/08/AU-market-dashboard-2026-08-23-0843.jpg "Australia Stock Market Today 23/08/2026 [UPDATE: 08:38 AEST] [Healthcare Surge: Weekly Recap and Week Ahead]")
Australia Stock Market Today 23/08/2026 [UPDATE: 08:38 AEST] [Healthcare Surge: Weekly Recap and Week Ahead]
Healthcare Surge: Weekly Recap and Week Ahead23/08/2026 · 08:38 AEST WEEKLY RECAP + WEEK AHEAD Healthcare broke away from a softer ASX CSL's reset-year result powered a sharp sector rotation. Banks and consumer names…
WEEKLY RECAP + WEEK AHEAD
Healthcare broke away from a softer ASX
CSL's reset-year result powered a sharp sector rotation. Banks and consumer names carried the downside; inflation and a dense earnings slate now set the next test.
ASX CASH MARKET CLOSED
Sunday non-trading day
Dashboard updated: 23 Aug 2026, 08:43 AEST (UTC+10)
Market data: latest close, 21 Aug 2026, about 16:10 AEST
Week in one frame
Index dataWeekly changes compare the 21 Aug close with 14 Aug. Sector figures are calculated from published closes and may differ slightly from vendor summaries.
What drove it
CSL FY26- CSL reset: US$3.1bn underlying NPATA, US$3.5bn operating cash flow and about 5% FY27 underlying NPAT growth guidance outweighed a US$2.6bn statutory loss after US$7.1bn of impairments.
- Banks reversed: financials fell about 5.1% over the week; CBA alone lost 5.15%, making the index's defensive healthcare surge look even more concentrated.
- Friday split: GYG jumped 11.5% after a 29.7% profit increase, while Zip fell 14.4%, Telix 10.1% and Super Retail 7.5%.
- Oil risk: Brent finished near US$93.49/bbl on Friday. The Iran risk premium helped energy but revived inflation and bond-yield concerns.
Week ahead
Scheduled events - AEST (UTC+10)ASX reopens
Opening single-price auction from 09:59; continuous trading follows. Results include Bendigo Bank, Ampol, Endeavour, PLS and Reece.
RBA minutes - 11:30
David Jacobs speaks at 14:00. Coles, Woodside, Scentre and Viva Energy are scheduled to report.
July CPI - 11:30
June CPI was 3.8% y/y and trimmed mean 3.6% y/y. Domino's, Flight Centre and Lynas are among the scheduled results.
Capex + RBA Bulletin - 11:30
Private capital expenditure and the RBA Bulletin land together; reporting season remains active.
Bull case
CSL's rebound broadens into health care and CPI eases enough to cap yields. Holding 9,000 while breadth improves would support a rotation-led recovery.
Bear case
Sticky CPI, firm oil and a 10-year yield above 5% pressure bank, property and consumer multiples while earnings misses spread beyond isolated names.
Watch first
ASX 200: 9,000 support, then 9,115 resistance. Also watch financial-sector stabilisation, AUD/USD 0.71 and whether VIX stays near 10.5.
CSL Shares Surge 23% During Reset Week, Surpassing Analysts’ A$163.62 Price Target
CSL Limited finished its strongest week in several years, closing above the consensus analyst price target. Shares settled at A$168.30 on Friday, August 21, following a 23.3% rise over five trading days. The surge boosted CSL's market capitalisation by about A$14.5 billion.
CSL
ASX:CSL · Investor dashboard
The reset rally meets its first valuation test
Weekend snapshot · 23 August 2026 · all prices in Australian dollars unless noted
ASX CLOSED · REOPENS MON 10:00 AEST
Friday close
A$168.30
21 Aug 2026 · 16:11 AEST closing auction
Weekly return
+23.3%
From A$136.50 on 14 Aug
Friday session
−1.7%
A$166.28–A$171.54 range
Market value
A$80.6bn
Buyback equals about 1.4% of value
Six-session price path: results did the heavy lifting
Why the stock moved
Cash earnings survived the write-downUS$3.10bn underlying NPATA and US$3.51bn operating cash flow softened a US$2.58bn statutory loss.
Growth returned to the guideManagement expects about 5% FY27 underlying NPAT growth at constant currency.
Cost savings became measurableUS$176m delivered in FY26; US$400m is targeted in FY27.
Capital returnedA$1.1bn buyback planned, though it is too small to explain a 23% weekly rerating alone.
Analysts: price moved ahead of the pack
ConsensusBUY · 7 Buy / 9 Hold / 0 Sell
The average target implies 2.8% downside. The high target offers 22.1% upside; the low target implies 21.5% downside.
FY26 revenue mix and FY27 direction
CSL Behring · US$11.39bnmid-single-digit growth
CSL Vifor · US$2.38bnabout −25%
CSL Seqirus · US$2.03bnlow-single-digit growth
Vifor's guide implies an estimated US$595m revenue headwind. Behring must carry the group while total revenue stays broadly flat.
FY27 bridge
| Measure | Guide |
|---|---|
| Revenue | Broadly flat |
| Underlying NPAT | ~+5% |
| Cost savings | US$400m |
| Capex | US$1.0bn ± US$100m |
| FX sensitivity | ~US$50m headwind |
| Net debt / EBITDA | 1.8× |
What would confirm—or break—the rerating
ConfirmationImmunoglobulin keeps its 7% second-half momentum; ANDEMBRY and HEMGENIX scale; FY27 savings arrive without slowing commercial execution.
Failure pointsVifor falls faster than 25%; Chinese albumin pricing stays weak; US flu demand softens; a permanent CEO search drags into another reporting cycle.
CSL Stock Adds A$16 Billion as Investors Price a 5% Profit Rebound
CSL Limited added an estimated A$16.1 billion in market value during results week. The shares ended Friday at A$168.30, up 25.0% from Monday's A$134.60 close. They slipped 1.69% in the final session as the Australian market closed for the weekend.
ASX:CSL · RESULTS-WEEK RESET
CSL Limited Investor Dashboard
FY26 results, FY27 recovery targets and the market re-rating
A$168.30Friday −1.69% · Week +25.04%
Close: 21 Aug 2026, 16:00 AEST
Value added vs Monday≈A$16.1bnUsing 478.91m shares
FY26 revenueUS$15.80bn−1% at constant currency
FY27 profit guide≈+5%Underlying NPAT, constant FX
FY27 buybackA$1.1bn≈1.3% of market value
Results-week re-rating
Where the recovery must come from
Broker check after results
| Broker | Call | Target |
|---|---|---|
| UBS | Buy | A$181 |
| CLSA | Outperform | A$180 |
| Macquarie | Hold | A$108 |
| Current aggregate | Buy | A$163.62 |
Investor read-through: the market has already priced a sizable recovery. The next proof points are Behring margin expansion, US$400 million of savings and control of Vifor's expected decline. A weak delivery could expose the gap between Friday's close and the A$163.62 aggregate target.
Sources: CSL FY26 Results and FY26 Investor Presentation; Investing.com market data and post-result broker changes; StockAnalysis analyst history and shares outstanding. Market data timestamp: 21 Aug 2026, 16:00 AEST. Figures are in USD unless marked A$.
Australia Stock Market Today 22/08/2026 [UPDATE: 08:37 AEST] [Weekly Recap and Week Ahead: Healthcare Leads, CPI Looms]
Weekly Recap and Week Ahead: Healthcare Leads, CPI Looms08.22.2026 · 08:37 AEST WEEKEND EDITION · CASH MARKET CLOSED Weekly Recap + Week Ahead Healthcare and materials carried the tape; rate-sensitive and consumer shares did…
WEEKEND EDITION · CASH MARKET CLOSED
Weekly Recap + Week Ahead
Healthcare and materials carried the tape; rate-sensitive and consumer shares did the damage. CPI and a dense results calendar now set the next test.
Updated
22 Aug 2026 · 08:37 AEST
Latest cash close: Fri 21 Aug
ASX cash equities: closed for Saturday.
Next regular session: Monday 24 Aug; opening auction from 09:59 AEST, continuous trading from about 09:59:45 AEST.
ASX hours
WEEK IN ONE VIEW
Rotation, not capitulation
The benchmark slipped for a second week, but smaller companies finished ahead. Leadership was narrow and earnings-led: healthcare and materials rose while discretionary, financials and property sold off.
*Weekly moves calculated from Market Index sector and benchmark snapshots on 14 Aug at 17:00 AEST and 21 Aug at 14:48 AEST; historical, not live. 21 Aug data · 14 Aug data
CROSS-ASSET READ
Oil up, dollar firm
AUD/USD0.7140+0.38%
21 Aug, 14:48 AEST · late-session snapshot
Brent crudenear US$93/bblinflation pressure
21 Aug, 08:25 AEST · morning market snapshot
Higher oil supported local energy shares but renewed the inflation and long-bond risk facing property, retailers and other duration-sensitive stocks.
EARNINGS TAPE
What moved and why
CSL / Health careSector +9.5% for the week*
CSL reported FY26 underlying NPAT of US$3.10bn and EPS of 643 cents, both just above consensus; the 292-cent dividend missed the 298.1-cent estimate.
Guzman y Gomez+11.3% Friday
Shares jumped after the restaurant group reported 29.7% annual profit growth; the reaction stood out on a weak consumer day.
Equity Trustees+9.3% Friday
A takeover offer put the stock among the session's strongest deal-driven movers.
Inghams−7.2% Friday
Bird-flu warnings and elevated transport costs outweighed the broader energy bid.
Commonwealth Bank−5.15% week
The market's largest bank was a major drag as investors rotated away from expensive financials.
REITs and retailersReal estate −4.5%; discretionary −6.8%*
The worst weekly groups remained exposed to high yields, stretched valuations and fragile household demand.
Latest reported prices and catalysts: 21 Aug market close. CSL result/consensus: Market Index results calendar.
BULL / BEAR
The setup into Monday
Bull case
Small caps beat the benchmark, while healthcare and materials absorbed selling elsewhere. A softer CPI print would ease duration pressure and broaden the rally.
Bear case
Discretionary, banks, property and tech all weakened together. Sticky CPI or another oil leg higher would keep yields and valuation compression in control.
9,000 first psychological support
9,115.2 prior Friday close
9,263.6 7 Aug reference high-close
WEEK AHEAD · AEST
Calendar that can move the index
- ASX reopensOpening auction from 09:59; continuous trading from about 09:59:45.
- Results: ALD, BEN, EDV, PLS, REH, VNTConsensus figures are estimates; dates may change.
- Results: COL, SCG, WDSRBA domestic-markets speech at 14:00.
- July CPIConsensus cited by IG: headline 3.5% y/y; trimmed mean around 3.6%. Estimate, not an official forecast.
- Results: DMP, FLT, LYC, WOW, WTCConsumer, travel, resources and technology in focus.
- Private capital expenditureJune-quarter reference period; ABS scheduled release.
- Results: MIN, QAN, RHC, S32, WESRBA Bulletin also scheduled for 11:30.
CSL Shares Continue Gains After Results, Surpass Analyst Price Estimates
CSL Limited added roughly A$14.5 billion in market capitalisation across two sessions as investors overlooked a record statutory loss and concentrated on steadying earnings.
ASX:CSL · Results reset
CSL’s rebound outruns the old targets
The market is pricing a cleaner FY27 before brokers have caught up.
ASX closed · Reopens 20 Aug, 10:00 AEST
A$166.48
Close · 19 Aug 2026, 16:10 AEST
+23.7%
Two-session move
A$75.58bn
Market capitalisation
2.96×
Relative volume · 3.88m shares
Price versus pre-results targets
Wednesday’s close is 19.6% above the A$139.20 average target. Published targets may now move, but the rally has already priced part of that revision.
FY26: cash earnings versus write-downs
RevenueUS$15.8bn −1%
Underlying NPATAUS$3.1bn −2%
Operating cash flowUS$3.5bn
Pre-tax impairmentsUS$7.1bn
Statutory resultUS$2.6bn loss
Leverage 1.8×FY27 NPAT +~5%Revenue broadly flatRevenue engine
Behring supplies roughly 72% of group revenue. Vifor revenue is guided about 25% lower in FY27.
What the next week tests
- Broker revisions: all named pre-results targets sit below spot.
- Buyback support: the new A$1.1bn programme equals about 1.5% of market value.
- Profit quality: investors need stable Behring margins, not another accounting reset.
- Leadership: the permanent chief-executive search remains open.
Recommendation mix · 7 Aug snapshot
Risk gauge
Vifor FY27 declineHigh
China albumin pricingElevated
US vaccine demandElevated
Balance-sheet pressureContained
Sources: TradingView, CSL FY26 results summary, S&P Global analyst poll and CSL investor calendar. Financial figures are in US dollars unless marked A$. Market data as of 19 Aug 2026, 16:10 AEST.
ASX 200 Steady at Close After Volatile Earnings Shifts Ahead of Wage Report
Australian stocks were poised to begin Wednesday’s session weaker. The S&P/ASX 200 closed Tuesday at 9,070.0, down 3.2 points, or 0.04%. At this update, the cash market was still in pre-open; regular trading is scheduled for approximately 09:59:45 in Sydney.
Australia · pre-open investor brief
Cash market pre-open
The index remains flat, but volatility among individual stocks is high.
Healthcare climbed, but lingering weakness in banks kept the benchmark unchanged. As financials and materials make up 59.23% of the index, sector leadership outweighs market breadth.
Snapshot taken at 19 Aug 2026, 08:55:36 AEST (UTC+10). Regular ASX trade starts at 09:59:45 AEST, followed by a randomised 15-second opening window. ASX hours
18 Aug 2026 close; reported 16:29 AEST (UTC+10) by ABC
Five consecutive declines wiped out the early-August gains
S&P/ASX 200 daily closing values from 4 to 18 Aug 2026; AEST trading sessions (UTC+10)
Series: Investing.com historical data. Closing prices are provided after the ASX closing auction, typically finishing at around 16:11 Sydney time.
Why an ≈+8.1% rise in healthcare failed to boost the index
Index weights as of 18 Aug 2026 close; source does not specify clock time or time zone
Investor read-through: The session lacked widespread calm, with only a niche segment posting a sharp recovery. Banking-heavy core areas continued to act as a drag on the index.
Weights sourced from State Street STW, 18 Aug 2026. Market changes from 18 Aug 2026 close; health sector movement checked with ABC at 16:29 AEST.
Shares to be paid a fully franked dividend of A$2.70 each. The ex-date starts at the ASX opening phase on 19 Aug 2026 at 09:59:45 AEST (UTC+10). This may exert automatic downward pressure on the price index, all other factors being unchanged. CBA dividend
The Wage Price Index will be released at 11:30 AEST (UTC+10). The previous quarter climbed 0.8%, with annual growth at 3.3%. This data has the potential to shift rate forecasts for the banking, property, and retail sectors. ABS schedule
Santos, Evolution Mining, Temple & Webster, Breville, Mirvac and Whitehaven Coal are listed as companies due to release reports. The source did not specify exact release times. Morningstar/AAP
Primary sources: ABC market close RBA decision ASX trading hours Data-quality note: there was no verified, time-stamped official SPI 200 pre-open quote at 08:55:36 AEST, so the futures figure is omitted. The calculated values are 59.23% (32.61% plus 26.62%), −1.95% (from 9,250.6 down to 9,070.0), and −2.44% (from 9,296.7 to 9,070.0).
CSL Limited (ASX:CSL) Stock Ends Week Down 7.4% as HEMGENIX Progress Faces Scale Test
CSL Limited enters Monday after five straight losses erased 7.4% from its share price, Friday-to-Friday. Shares closed Friday at A$114.22, down 1.3% on the day. The ASX cash market was closed at publication; pre-open begins at 07:00 AEST.
CSL (ASX:CSL) shares rebound A$16 billion off lows, lag plasma sector for week
CSL Limited has regained roughly A$16 billion in market value from its 52-week low, but last week's slight rise lagged behind two competitors involved in plasma.
CSL Limited (ASX:CSL) awaits US$650 million hurdle ahead of August results, pressuring rebound
CSL Limited gained 1.12% to close at A$123.32 on Friday. The S&P/ASX 200 index slipped 0.50%. Sydney’s cash market remained closed on Saturday morning.
CSL Share Price Has Won Back A$15 Billion — Now Investors Want Revenue Proof
CSL Limited entered Tuesday’s ASX pre-open after falling 1.26% to A$121.34 on Monday, while the S&P/ASX 200 edged 0.03% higher. Turnover reached 1.50 million shares, 34% above the average of the previous five sessions. The exchange remained in pre-open at publication, with continuous trading due to begin around 10 a.m. Sydney time.
Australian Securities Exchange Weekly Wrap: ASX 200 Sheds A$130 Billion as Middle East War and Rate Risks Rattle Stocks
Australian stocks took a hard hit last week, with the S&P/ASX 200 tumbling 3.8% amid escalating concerns over the Middle East conflict. Investors saw around A$130 billion in value erased from the market. On Friday, the index sank another 1%, which wiped out close to half the gains made in February.
CSL share price ticks up on buyback update as investors line up key March dates
CSL Limited settled 0.5% higher at A$146.76 Friday, having swung from A$145.07 to A$147.53 through the session as roughly 1.68 million shares traded. The stock finished just about A$2 clear of its 52-week low at A$144.61, according to data.
CSL share price slips again as buyback rolls on, March dividend date looms
CSL Ltd closed down 1.5% on Tuesday at A$145.13, slipping from an open of A$148.10 before ending the day on the session’s low. The stock has now dropped 5.3% across the last two sessions.
CSL share price slips as buyback tally grows; Lilly deal sets up next week
CSL Ltd slipped 0.6% Friday, ending the session at A$153.27. That pullback shaved off some of the gains from a two-day run-up earlier in the week.
CSL stock price ends higher after Eli Lilly clazakizumab deal, with buyback in the background
CSL Ltd jumped up to 2.1% on Wednesday after the Australian biotech signed a licensing agreement with Eli Lilly for clazakizumab, an investigational antibody currently in trials for end-stage kidney disease.
CSL share price slips after fresh buyback filing — what investors watch next
CSL Limited slipped 0.4% to finish at A$151.56 on Tuesday, lagging behind the S&P/ASX 200’s 0.2% gain. The stock has lost roughly 14% since early February, hit by a steep drop during profit season.
ASX 200 today: Australian shares finish flat as AI fears hit insurers; CSL slides 5%
Australian stocks closed almost flat Tuesday, the S&P/ASX 200 shedding just 2.7 points, or 0.03%, to settle at 8,867.40. Insurance brokers took a hit as renewed AI competition fears surfaced. Miners, gold names, and tech all moved higher. “A peer releasing an app has wiped billions off the market capitalisations of the insurance broking sector,” said Luke Winchester, portfolio manager at Merewether Capital.
CSL CEO exit jolts ASX even as Nvidia lifts tech mood
CSL shares slid 4.98% Tuesday after the Australian biotech announced CEO Paul McKenzie’s retirement and tapped director Gordon Naylor as interim chief, effective Feb. 11. The S&P/ASX 200, which spent much of the day in positive territory, ended almost flat—off 0.03% at 8,867.4.
CSL CEO Paul McKenzie retires ahead of results, sending shares lower as Gordon Naylor steps in
CSL announced Tuesday that chief executive and managing director Paul McKenzie is stepping down. Gordon Naylor, a veteran executive at the company, will assume the interim CEO role starting Feb. 11.
CSL share price rises as CEO McKenzie steps down, spotlight turns to half-year results
CSL Ltd announced chief executive Paul McKenzie’s retirement, tapping former executive Gordon Naylor as interim replacement. Shares in CSL ended Tuesday 1.7% higher at A$183.44.
TechStock² Updates
